Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

Abstract Background The 8th edition of the American Joint Committee on Cancer (AJCC) staging has introduced prognostic stage based on anatomic stage combined with biologic factors. We aimed to validate the prognostic stage in HER2-positive breast cancer patients enrolled in the ShortHER trial. Metho...

Full description

Bibliographic Details
Main Authors: Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes, Antonio Frassoldati, Luigi Cavanna, Francesco Giotta, Michele Aieta, Vittorio Gebbia, Antonino Musolino, Ornella Garrone, Michela Donadio, Anita Rimanti, Alessandra Beano, Claudio Zamagni, Hector Soto Parra, Federico Piacentini, Saverio Danese, Antonella Ferro, Katia Cagossi, Samanta Sarti, Anna Rita Gambaro, Sante Romito, Viviana Bazan, Laura Amaducci, Gabriella Moretti, Maria Pia Foschini, Sara Balduzzi, Roberto Vicini, Roberto D’Amico, Gaia Griguolo, Valentina Guarneri, Pier Franco Conte
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Medicine
Subjects:
HER2-positive
Breast cancer
Trastuzumab
Prognostic stage
8th AJCC
Online Access:http://link.springer.com/article/10.1186/s12916-019-1445-z

Internet

http://link.springer.com/article/10.1186/s12916-019-1445-z

Similar Items